The Next Generation Biotech Media
By T. Chakraborty, Ph.D. & Rajaneesh K. Gopinath, Ph.D. On October 22nd, Atea Pharmaceuticals, Inc. announced that it had entered into an arrangement with Roche for the exclusive rights to …
Read More
By Daniel Ojeda, Ph.D. On October 22nd, Remdesivir (Veklury) was approved by the U.S. Food and Drug Administration (FDA) to treat patients with COVID-19. The approval comes days after the …
Read More
By T. Chakraborty, Ph.D. In the last couple of decades, genome editing techniques have revolutionized various aspects of biological research. With improvements in technology over time, the scientific community is …
Read More
By Tyler Chen On October 12th, Taiwan’s TTY Biopharm Company Limited received the authorization for delivering COVID-19 vaccines produced by BioNTech. Around 30 million vaccines will be delivered to Taiwan, …
Read More
By Rajaneesh K. Gopinath, Ph.D. China-based Sinovac Biotech may initiate a Phase 3 clinical trial of its inactivated COVID-19 vaccine, CoronaVac, in the Philippines as early as next month. Philippine …
Read More
By Sahana Shankar, Ph.D. Candidate It is now common knowledge that the Spike protein (S) on the surface of SARS-CoV-2 is responsible for host entry, a step that the virus …
Read More
By Sangeeta Chakraborty, Ph.D. Indianapolis-based Eli Lilly’s leading antibody treatment for coronavirus, currently in three major clinical trials, recently came under the scrutiny of government health officials who asked the …
Read More
By Ruchi Jhonsa, Ph.D. In a statement, late night on 12th October, Johnson and Johnson said it had paused all the dosing in Phase 3 clinical trial of its experimental …
Read More
By Pavel Ryzhov, Ph.D. The clinical trial landscape for COVID-19 treatment options has been steadily growing as the pandemic enters the fourth quarter of 2020. Many companies, including Gilead, Regeneron, …
Read More
By T. Chakraborty, Ph.D. As the clock keeps ticking, scientists worldwide are trying their best to develop an effective cure for COVID-19. Among the frontrunners, Moderna and AstraZeneca’s vaccine candidates …
Read More